Zhi Tong Cai Jing·2025-08-19 15:28Major Events - CSPC Pharmaceutical Group (01093) received clinical trial approval for Dupilumab injection in China [1] - Rongchang Bio (09995) was granted breakthrough therapy designation for RC148 for non-small cell lung cancer by the National Medical Products Administration [1] - China Biologic Products (01177) included LM-302 "CLDN18.2 ADC" in the breakthrough therapy program [1] - Sunshine Oilsands (02012) plans to acquire 51% of Noble Technology Limited for HKD 50.91945 million [1] - Galenica Pharmaceutical-B (01672) plans a placement at a discount of approximately 9.9%, raising HKD 468 million [1] Operating Performance - Xiaomi Group-W (01810) reported record high revenue and profit for Q2, with attributable profit of HKD 11.904 billion, a year-on-year increase of 133.51% [1] - Pop Mart (09992) announced a mid-term profit attributable to shareholders of HKD 4.574 billion, a year-on-year increase of 396.5% [1] - Fuyao Glass (03606) reported a half-year net profit of approximately HKD 4.805 billion, a year-on-year increase of 37.33% [1] - China Resources Beer (00291) reported a mid-term profit attributable to shareholders of HKD 5.789 billion, a year-on-year increase of 23.04% [1] - Kunlun Energy (00135) reported a mid-term profit attributable to shareholders of HKD 3.161 billion, a year-on-year decrease of 4.36%, with a dividend of HKD 0.166 per share [1] - WuXi Biologics (02269) reported a mid-term profit attributable to shareholders of approximately HKD 2.339 billion, a year-on-year increase of 56% [1] - Sunny Optical Technology (02382) reported a mid-term profit attributable to shareholders of HKD 1.646 billion, a year-on-year increase of 52.56% [1] - Yixin Group (02858) reported an adjusted net profit of HKD 648 million, a year-on-year increase of 28% [1] - Kangchen Pharmaceutical (01681) reported a mid-term profit attributable to shareholders of HKD 498 million, a year-on-year increase of 24.6%, maintaining market leadership with its flagship product [1] - Ping An Good Doctor (01833) reported a mid-term profit attributable to shareholders of HKD 134 million, a year-on-year increase of 136.84% [1] - China Communication Services (02342) reported a mid-term profit attributable to shareholders of HKD 61.781 million, returning to profitability [1] - XPeng Motors-W (09868) reported record levels in core business and financial metrics for Q2, with a net loss attributable to ordinary shareholders of HKD 480 million, narrowing by 62.8% year-on-year [1] - Guochuang Tongqiao (02190) reported a mid-term profit attributable to shareholders of HKD 121 million, a year-on-year increase of 76% [1] - Yanda Pharmaceutical (00512) reported record revenue of HKD 6.107 billion [1] - Jinli Permanent Magnet (06680) reported a mid-term net profit of approximately HKD 305 million, a year-on-year increase of 154.81% [1] - Zhaogang Group-W (06676) issued a profit warning, expecting a mid-term profit attributable to shareholders of approximately HKD 140 million to HKD 180 million, returning to profitability [1] - Longyuan Power (00916) reported a mid-term profit attributable to equity holders of HKD 3.519 billion, a year-on-year decrease of 14.4% [1] - Yancoal Australia (03668) reported a mid-term profit attributable to shareholders of AUD 16.3 million, a year-on-year decrease of 61.19% [1] - SF Holding (06936) reported combined revenue of HKD 24.847 billion from express logistics, supply chain, and international business in July, a year-on-year increase of 9.95% [1] - Chow Sang Sang (00116) expects a mid-term profit attributable to shareholders from continuing operations of approximately HKD 900 million to HKD 920 million [1]